Hepcidin resistance in dysmetabolic iron overload

Background & Aims Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains poorly defined. Aim of this study was to characterize iron metabolism in DIOS. Methods We evaluated 18 patients with DIOS,...

Full description

Saved in:
Bibliographic Details
Published inLiver international Vol. 36; no. 10; pp. 1540 - 1548
Main Authors Rametta, Raffaela, Dongiovanni, Paola, Pelusi, Serena, Francione, Paolo, Iuculano, Federica, Borroni, Vittorio, Fatta, Erika, Castagna, Annalisa, Girelli, Domenico, Fargion, Silvia, Valenti, Luca
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.10.2016
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background & Aims Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains poorly defined. Aim of this study was to characterize iron metabolism in DIOS. Methods We evaluated 18 patients with DIOS, compared to 18 with nonalcoholic fatty liver and 23 healthy individuals with normal iron status, and 10 patients with hereditary haemochromatosis by a 24‐h oral iron tolerance test with hepcidin measurement and iron metabolism modelling under normal iron stores. Results Dysmetabolic iron overload syndrome patients had higher peak transferrin saturation and area under the‐curve of transferrin saturation than subjects with normal iron status, but lower values than haemochromatosis patients (P < 0.05 for all). Conversely, they had higher peak circulating hepcidin levels and area under the curve of hepcidin than the other groups (P < 0.05 for all). This was independent age, sex, haemoglobin, ferritin, and transferrin saturation levels (P = 0.0002). Hepcidin increase in response to the rise in transferrin saturation (hepcidin release index) was not impaired in DIOS patients. Viceversa, the ability of the hepcidin spike to control the rise in transferrin saturation at the beginning of the test (hepcidin resistance index) was impaired in DIOS (P = 0.0002). In DIOS patients, the hepcidin resistance index was correlated with ferritin levels at diagnosis (P = 0.016). Conclusions Dysmetabolic iron overload syndrome is associated with a subtle impairment in the ability of the iron hormone hepcidin to restrain iron absorption following an iron challenge, suggesting a hepcidin resistance state. Further studies are required to better characterize the molecular mechanism underpinning this new iron metabolism alteration.
AbstractList Background & Aims Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains poorly defined. Aim of this study was to characterize iron metabolism in DIOS. Methods We evaluated 18 patients with DIOS, compared to 18 with nonalcoholic fatty liver and 23 healthy individuals with normal iron status, and 10 patients with hereditary haemochromatosis by a 24‐h oral iron tolerance test with hepcidin measurement and iron metabolism modelling under normal iron stores. Results Dysmetabolic iron overload syndrome patients had higher peak transferrin saturation and area under the‐curve of transferrin saturation than subjects with normal iron status, but lower values than haemochromatosis patients (P < 0.05 for all). Conversely, they had higher peak circulating hepcidin levels and area under the curve of hepcidin than the other groups (P < 0.05 for all). This was independent age, sex, haemoglobin, ferritin, and transferrin saturation levels (P = 0.0002). Hepcidin increase in response to the rise in transferrin saturation (hepcidin release index) was not impaired in DIOS patients. Viceversa, the ability of the hepcidin spike to control the rise in transferrin saturation at the beginning of the test (hepcidin resistance index) was impaired in DIOS (P = 0.0002). In DIOS patients, the hepcidin resistance index was correlated with ferritin levels at diagnosis (P = 0.016). Conclusions Dysmetabolic iron overload syndrome is associated with a subtle impairment in the ability of the iron hormone hepcidin to restrain iron absorption following an iron challenge, suggesting a hepcidin resistance state. Further studies are required to better characterize the molecular mechanism underpinning this new iron metabolism alteration.
Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains poorly defined. Aim of this study was to characterize iron metabolism in DIOS. We evaluated 18 patients with DIOS, compared to 18 with nonalcoholic fatty liver and 23 healthy individuals with normal iron status, and 10 patients with hereditary haemochromatosis by a 24-h oral iron tolerance test with hepcidin measurement and iron metabolism modelling under normal iron stores. Dysmetabolic iron overload syndrome patients had higher peak transferrin saturation and area under the-curve of transferrin saturation than subjects with normal iron status, but lower values than haemochromatosis patients (P < 0.05 for all). Conversely, they had higher peak circulating hepcidin levels and area under the curve of hepcidin than the other groups (P < 0.05 for all). This was independent age, sex, haemoglobin, ferritin, and transferrin saturation levels (P = 0.0002). Hepcidin increase in response to the rise in transferrin saturation (hepcidin release index) was not impaired in DIOS patients. Viceversa, the ability of the hepcidin spike to control the rise in transferrin saturation at the beginning of the test (hepcidin resistance index) was impaired in DIOS (P = 0.0002). In DIOS patients, the hepcidin resistance index was correlated with ferritin levels at diagnosis (P = 0.016). Dysmetabolic iron overload syndrome is associated with a subtle impairment in the ability of the iron hormone hepcidin to restrain iron absorption following an iron challenge, suggesting a hepcidin resistance state. Further studies are required to better characterize the molecular mechanism underpinning this new iron metabolism alteration.
Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains poorly defined. Aim of this study was to characterize iron metabolism in DIOS.BACKGROUND & AIMSDysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains poorly defined. Aim of this study was to characterize iron metabolism in DIOS.We evaluated 18 patients with DIOS, compared to 18 with nonalcoholic fatty liver and 23 healthy individuals with normal iron status, and 10 patients with hereditary haemochromatosis by a 24-h oral iron tolerance test with hepcidin measurement and iron metabolism modelling under normal iron stores.METHODSWe evaluated 18 patients with DIOS, compared to 18 with nonalcoholic fatty liver and 23 healthy individuals with normal iron status, and 10 patients with hereditary haemochromatosis by a 24-h oral iron tolerance test with hepcidin measurement and iron metabolism modelling under normal iron stores.Dysmetabolic iron overload syndrome patients had higher peak transferrin saturation and area under the-curve of transferrin saturation than subjects with normal iron status, but lower values than haemochromatosis patients (P < 0.05 for all). Conversely, they had higher peak circulating hepcidin levels and area under the curve of hepcidin than the other groups (P < 0.05 for all). This was independent age, sex, haemoglobin, ferritin, and transferrin saturation levels (P = 0.0002). Hepcidin increase in response to the rise in transferrin saturation (hepcidin release index) was not impaired in DIOS patients. Viceversa, the ability of the hepcidin spike to control the rise in transferrin saturation at the beginning of the test (hepcidin resistance index) was impaired in DIOS (P = 0.0002). In DIOS patients, the hepcidin resistance index was correlated with ferritin levels at diagnosis (P = 0.016).RESULTSDysmetabolic iron overload syndrome patients had higher peak transferrin saturation and area under the-curve of transferrin saturation than subjects with normal iron status, but lower values than haemochromatosis patients (P < 0.05 for all). Conversely, they had higher peak circulating hepcidin levels and area under the curve of hepcidin than the other groups (P < 0.05 for all). This was independent age, sex, haemoglobin, ferritin, and transferrin saturation levels (P = 0.0002). Hepcidin increase in response to the rise in transferrin saturation (hepcidin release index) was not impaired in DIOS patients. Viceversa, the ability of the hepcidin spike to control the rise in transferrin saturation at the beginning of the test (hepcidin resistance index) was impaired in DIOS (P = 0.0002). In DIOS patients, the hepcidin resistance index was correlated with ferritin levels at diagnosis (P = 0.016).Dysmetabolic iron overload syndrome is associated with a subtle impairment in the ability of the iron hormone hepcidin to restrain iron absorption following an iron challenge, suggesting a hepcidin resistance state. Further studies are required to better characterize the molecular mechanism underpinning this new iron metabolism alteration.CONCLUSIONSDysmetabolic iron overload syndrome is associated with a subtle impairment in the ability of the iron hormone hepcidin to restrain iron absorption following an iron challenge, suggesting a hepcidin resistance state. Further studies are required to better characterize the molecular mechanism underpinning this new iron metabolism alteration.
Author Francione, Paolo
Rametta, Raffaela
Iuculano, Federica
Borroni, Vittorio
Girelli, Domenico
Castagna, Annalisa
Pelusi, Serena
Valenti, Luca
Dongiovanni, Paola
Fargion, Silvia
Fatta, Erika
Author_xml – sequence: 1
  givenname: Raffaela
  surname: Rametta
  fullname: Rametta, Raffaela
  organization: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
– sequence: 2
  givenname: Paola
  surname: Dongiovanni
  fullname: Dongiovanni, Paola
  organization: Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy
– sequence: 3
  givenname: Serena
  surname: Pelusi
  fullname: Pelusi, Serena
  organization: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
– sequence: 4
  givenname: Paolo
  surname: Francione
  fullname: Francione, Paolo
  organization: Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy
– sequence: 5
  givenname: Federica
  surname: Iuculano
  fullname: Iuculano, Federica
  organization: Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy
– sequence: 6
  givenname: Vittorio
  surname: Borroni
  fullname: Borroni, Vittorio
  organization: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
– sequence: 7
  givenname: Erika
  surname: Fatta
  fullname: Fatta, Erika
  organization: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
– sequence: 8
  givenname: Annalisa
  surname: Castagna
  fullname: Castagna, Annalisa
  organization: Policlinico G.B. Rossi, Department of Medicine, Università di Verona, Verona, Italy
– sequence: 9
  givenname: Domenico
  surname: Girelli
  fullname: Girelli, Domenico
  organization: Policlinico G.B. Rossi, Department of Medicine, Università di Verona, Verona, Italy
– sequence: 10
  givenname: Silvia
  surname: Fargion
  fullname: Fargion, Silvia
  organization: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
– sequence: 11
  givenname: Luca
  surname: Valenti
  fullname: Valenti, Luca
  email: luca.valenti@unimi.it, luca.valenti@unimi.it
  organization: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26998752$$D View this record in MEDLINE/PubMed
BookMark eNp1kMtOwzAQRS1URGlhwQ-gLGGRNmMnTrxEFX2ICiQKZWk5jiMZ3LjYaaF_T6CPBYLZeCydc6W5HdSqbKUQuoCoB830jV73gACOj9ApxGkWEkygddgxaaOO969RBIwlcILamDKWpQk-RTBWS6kLXQVOee1rUUkVNL9i4xeqFrk1Wgba2Sqwa-WMFcUZOi6F8ep893bR8_D2aTAOpw-jyeBmGkpCSRyyqJRZjglNaU5pAUKQOMszIjMopFQkjUgUY5KwVAAVkGeqwEmCS5YyQnNZkC662uYunX1fKV_zhfZSGSMqZVeeQwYMmtsi3KCXO3SVL1TBl04vhNvw_ZkN0N8C0lnvnSq51LWota1qJ7ThEPHvInlTJP8psjGufxn70L_YXfqHNmrzP8ink_neCLdG07j6PBjCvXGakjThL_cjPrujbDgfzfgj-QLD3Y-G
CitedBy_id crossref_primary_10_3748_wjg_v29_i4_616
crossref_primary_10_1515_cclm_2023_0540
crossref_primary_10_1016_j_lpm_2017_05_036
crossref_primary_10_1016_j_metabol_2024_155953
crossref_primary_10_3390_jcm10092008
crossref_primary_10_1002_ajh_25679
crossref_primary_10_1111_liv_13513
crossref_primary_10_1016_j_clnu_2019_02_012
crossref_primary_10_3390_physiologia2010001
crossref_primary_10_1097_HCO_0000000000000511
crossref_primary_10_3390_endocrines4010002
crossref_primary_10_1016_j_aohep_2022_100707
crossref_primary_10_1016_j_ejphar_2019_172614
crossref_primary_10_17941_agd_1338597
crossref_primary_10_1194_jlr_P090449
crossref_primary_10_1146_annurev_nutr_071816_064559
crossref_primary_10_3390_ijms21103505
crossref_primary_10_1002_hep4_2012
crossref_primary_10_1111_jgh_15971
crossref_primary_10_1111_liv_14539
crossref_primary_10_1007_s00109_017_1596_3
crossref_primary_10_1111_liv_14333
crossref_primary_10_1210_clinem_dgad749
crossref_primary_10_1186_s12876_018_0804_0
crossref_primary_10_1038_s41574_023_00807_6
crossref_primary_10_32725_jab_2022_016
crossref_primary_10_1186_s10020_018_0008_7
crossref_primary_10_1111_apt_15173
Cites_doi 10.1016/j.numecd.2010.01.003
10.1530/eje.1.02083
10.1016/j.jhep.2009.01.029
10.3324/haematol.2009.010322
10.1111/j.1478-3231.2011.02520.x
10.1002/hep.21886
10.1016/j.jhep.2011.05.008
10.1016/j.jhep.2006.09.018
10.2337/diabetes.51.4.1000
10.1016/j.ajpath.2013.02.019
10.1016/j.jprot.2009.08.003
10.1093/qjmed/hcq170
10.1371/journal.pone.0048804
10.1126/science.1176639
10.1016/S0016-5085(99)70401-4
10.1172/JCI44421
10.3748/wjg.v20.i11.3002
10.1111/j.1572-0241.2007.01192.x
10.1371/journal.pone.0134635
10.1100/tsw.2011.130
10.3748/wjg.14.4745
10.1210/jc.2010-2682
10.1111/j.1478-3231.2004.0988.x
10.1182/blood-2011-02-337907
10.1016/S1590-8658(03)00025-2
10.2337/diacare.28.8.2061
10.1016/j.bcmd.2003.08.003
10.1053/j.gastro.2013.12.016
10.2337/dc05-1592
10.1053/j.gastro.2009.11.013
10.1002/hep.24038
10.2337/dc12-0505
10.3324/haematol.2010.033449
10.1159/000243791
10.1016/j.jhep.2008.09.011
10.1002/hep.27774
10.1016/j.jhep.2010.05.016
10.1053/gast.2002.32403
10.2337/diacare.23.1.57
10.1016/j.jhep.2008.03.011
10.1016/j.jhep.2010.05.023
10.2337/diacare.27.10.2422
10.3945/ajcn.111.015743
10.1371/journal.pone.0116855
ContentType Journal Article
Copyright 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Copyright_xml – notice: 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
– notice: 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1111/liv.13124
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1478-3231
EndPage 1548
ExternalDocumentID 26998752
10_1111_liv_13124
LIV13124
ark_67375_WNG_SK69FVGS_R
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Fondazione IRCCS Ca' Granda Ospedale Policlinico Milano
– fundername: Associazione Malattie Metaboliche del Fegato ONLUS
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OC
29L
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
X7M
XG1
ZXP
ZZTAW
~IA
~WT
AAHQN
AAIPD
AAMNL
AANHP
AAYCA
ACRPL
ACUHS
ACYXJ
ADNMO
AFWVQ
ALVPJ
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
ID FETCH-LOGICAL-c3634-90fc8b23676b66d1aa348b83c81dcce37030423597a16a1b8ed2552f97936bcd3
IEDL.DBID DR2
ISSN 1478-3223
1478-3231
IngestDate Fri Jul 11 11:55:53 EDT 2025
Wed Feb 19 02:40:33 EST 2025
Tue Jul 01 04:10:01 EDT 2025
Thu Apr 24 22:50:18 EDT 2025
Wed Jan 22 16:27:54 EST 2025
Wed Oct 30 09:51:30 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords iron
nonalcoholic fatty liver disease
liver
hereditary haemochromatosis
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3634-90fc8b23676b66d1aa348b83c81dcce37030423597a16a1b8ed2552f97936bcd3
Notes ark:/67375/WNG-SK69FVGS-R
Associazione Malattie Metaboliche del Fegato ONLUS
istex:74A026B96B6C4F7189190647D6AA7DE29A70B031
Fondazione IRCCS Ca' Granda Ospedale Policlinico Milano
ArticleID:LIV13124
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-8909-0345
PMID 26998752
PQID 1819122302
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_1819122302
pubmed_primary_26998752
crossref_citationtrail_10_1111_liv_13124
crossref_primary_10_1111_liv_13124
wiley_primary_10_1111_liv_13124_LIV13124
istex_primary_ark_67375_WNG_SK69FVGS_R
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-10
October 2016
2016-10-00
20161001
PublicationDateYYYYMMDD 2016-10-01
PublicationDate_xml – month: 10
  year: 2016
  text: 2016-10
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Liver international
PublicationTitleAlternate Liver Int
PublicationYear 2016
Publisher Blackwell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
References Trombini P, Paolini V, Pelucchi S, et al. Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome. Liver Int 2011; 31: 994-1000.
Mayr R, Janecke AR, Schranz M, et al. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol 2010; 53: 941-9.
Wrede CE, Buettner R, Bollheimer LC, et al. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol 2006; 154: 333-40.
Dongiovanni P, Lanti C, Gatti S, et al. High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload. PLoS ONE 2015; 10: e0116855.
Valenti L, Dongiovanni P, Fracanzani AL, et al. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003; 35: 172-8.
Acton RT, Barton JC, Passmore LV, et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 2006; 29: 2084-9.
Hoki T, Miyanishi K, Tanaka S, et al. Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis. Hepatology 2015; 62: 751-61.
Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011; 117: e218-25.
Fernandez-Real JM, Penarroja G, Castro A, et al. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002; 51: 1000-4.
Bozzini C, Girelli D, Olivieri O, et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005; 28: 2061-3.
Valenti L, Canavesi E, Galmozzi E, et al. Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2010b; 53: 927-33.
Haap M, Machann J, von Friedeburg C, et al. Insulin sensitivity and liver fat: role of iron load. J Clin Endocrinol Metab 2011; 96: 958-61.
Valenti L, Moscatiello S, Vanni E, et al. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling - a propensity score-adjusted observational study. QJM 2011b; 104: 141-9.
Camaschella C, Silvestri L. Molecular mechanisms regulating hepcidin revealed by hepcidin disorders. ScientificWorldJournal 2011; 11: 1357-66.
Gabrielsen JS, Gao Y, Simcox JA, et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest 2012; 122: 3529-40.
Riva A, Trombini P, Mariani R, et al. Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J Gastroenterol 2008; 14: 4745-52.
Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2011; 53: 448-57.
Ruivard M, Laine F, Ganz T, et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 2009; 50: 1219-25.
Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004; 27: 2422-8.
Valenti L, Fracanzani AL, Dongiovanni P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102: 1251-8.
Valenti L, Maloberti A, Signorini S, et al. Iron stores, hepcidin, and aortic stiffness in individuals with hypertension. PLoS ONE 2015; 10: e0134635.
Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 931-9.
Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007; 46: 1291-301.
Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
Vecchi C, Montosi G, Garuti C, et al. Gluconeogenic signals regulate iron homeostasis via hepcidin in mice. Gastroenterology 2014; 146: 1060-9.
Valenti L, Rametta R, Dongiovanni P, et al. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS ONE 2012; 7: e48804.
Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009; 122: 78-86.
Valenti L, Swinkels DW, Burdick L, et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2011a; 21: 568-75.
Zheng X, Jiang T, Wu H, et al. Hepatic iron stores are increased as assessed by magnetic resonance imaging in a Chinese population with altered glucose homeostasis. Am J Clin Nutr 2012; 94: 1012-9.
Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011; 55: 920-32.
Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol 2007; 46: 700-7.
Girelli D, Trombini P, Busti F, et al. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica 2011; 96: 500-6.
Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 2004; 32: 131-8.
Kroot JJ, Kemna EH, Bansal SS, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009; 94: 1748-52.
Dongiovanni P, Ruscica M, Rametta R, et al. Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol 2013; 182: 2254-63.
Valenti L, Fracanzani AL, Dongiovanni P, et al. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 2014; 20: 3002-10.
Vecchi C, Montosi G, Zhang K, et al. ER stress controls iron metabolism through induction of hepcidin. Science 2009; 325: 877-80.
Piperno A, Vergani A, Salvioni A, et al. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int 2004; 24: 471-6.
Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 2010; 73: 527-36.
Valenti L, Fracanzani AL, Bugianesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010a; 138: 905-12.
Barisani D, Pelucchi S, Mariani R, et al. Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. J Hepatol 2008; 49: 123-33.
Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Diabetes Care 2013; 36: 309-15.
Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-63.
Sorrentino P, D'Angelo S, Ferbo U, et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009; 50: 351-7.
2007; 102
2010; 53
2012; 122
2011; 117
2004; 27
2000; 23
2010a; 138
2002; 51
2015; 10
2004; 24
2008; 14
2003; 35
2011; 53
2011; 31
2011; 96
2011; 55
2006; 154
2011; 11
2010b; 53
2005; 28
2013; 182
2014; 20
2012; 94
2004; 32
2013; 36
2009; 50
2015; 62
2009; 94
2011b; 104
2002; 122
2008; 49
2011a; 21
2009; 122
2006; 29
1999; 117
2012; 7
2007; 46
2010; 73
2009; 325
2014; 146
e_1_2_8_28_1
e_1_2_8_29_1
e_1_2_8_24_1
e_1_2_8_25_1
e_1_2_8_26_1
e_1_2_8_27_1
e_1_2_8_3_1
e_1_2_8_2_1
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_43_1
e_1_2_8_21_1
e_1_2_8_42_1
e_1_2_8_22_1
e_1_2_8_45_1
e_1_2_8_23_1
e_1_2_8_44_1
e_1_2_8_41_1
e_1_2_8_40_1
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_39_1
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_36_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_15_1
e_1_2_8_38_1
e_1_2_8_16_1
e_1_2_8_37_1
e_1_2_8_32_1
e_1_2_8_10_1
e_1_2_8_31_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_30_1
References_xml – reference: Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol 2007; 46: 700-7.
– reference: Valenti L, Fracanzani AL, Bugianesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010a; 138: 905-12.
– reference: Hoki T, Miyanishi K, Tanaka S, et al. Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis. Hepatology 2015; 62: 751-61.
– reference: Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2011; 53: 448-57.
– reference: Ruivard M, Laine F, Ganz T, et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 2009; 50: 1219-25.
– reference: Wrede CE, Buettner R, Bollheimer LC, et al. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol 2006; 154: 333-40.
– reference: Dongiovanni P, Ruscica M, Rametta R, et al. Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol 2013; 182: 2254-63.
– reference: Valenti L, Maloberti A, Signorini S, et al. Iron stores, hepcidin, and aortic stiffness in individuals with hypertension. PLoS ONE 2015; 10: e0134635.
– reference: Valenti L, Swinkels DW, Burdick L, et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2011a; 21: 568-75.
– reference: Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004; 27: 2422-8.
– reference: Trombini P, Paolini V, Pelucchi S, et al. Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome. Liver Int 2011; 31: 994-1000.
– reference: Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
– reference: Bozzini C, Girelli D, Olivieri O, et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005; 28: 2061-3.
– reference: Kroot JJ, Kemna EH, Bansal SS, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009; 94: 1748-52.
– reference: Acton RT, Barton JC, Passmore LV, et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 2006; 29: 2084-9.
– reference: Piperno A, Vergani A, Salvioni A, et al. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int 2004; 24: 471-6.
– reference: Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 2010; 73: 527-36.
– reference: Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007; 46: 1291-301.
– reference: Valenti L, Moscatiello S, Vanni E, et al. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling - a propensity score-adjusted observational study. QJM 2011b; 104: 141-9.
– reference: Zheng X, Jiang T, Wu H, et al. Hepatic iron stores are increased as assessed by magnetic resonance imaging in a Chinese population with altered glucose homeostasis. Am J Clin Nutr 2012; 94: 1012-9.
– reference: Girelli D, Trombini P, Busti F, et al. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica 2011; 96: 500-6.
– reference: Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-63.
– reference: Valenti L, Canavesi E, Galmozzi E, et al. Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2010b; 53: 927-33.
– reference: Valenti L, Dongiovanni P, Fracanzani AL, et al. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003; 35: 172-8.
– reference: Sorrentino P, D'Angelo S, Ferbo U, et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009; 50: 351-7.
– reference: Gabrielsen JS, Gao Y, Simcox JA, et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest 2012; 122: 3529-40.
– reference: Valenti L, Fracanzani AL, Dongiovanni P, et al. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 2014; 20: 3002-10.
– reference: Camaschella C, Silvestri L. Molecular mechanisms regulating hepcidin revealed by hepcidin disorders. ScientificWorldJournal 2011; 11: 1357-66.
– reference: Fernandez-Real JM, Penarroja G, Castro A, et al. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002; 51: 1000-4.
– reference: Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 2004; 32: 131-8.
– reference: Valenti L, Rametta R, Dongiovanni P, et al. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS ONE 2012; 7: e48804.
– reference: Vecchi C, Montosi G, Garuti C, et al. Gluconeogenic signals regulate iron homeostasis via hepcidin in mice. Gastroenterology 2014; 146: 1060-9.
– reference: Haap M, Machann J, von Friedeburg C, et al. Insulin sensitivity and liver fat: role of iron load. J Clin Endocrinol Metab 2011; 96: 958-61.
– reference: Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011; 117: e218-25.
– reference: Mayr R, Janecke AR, Schranz M, et al. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol 2010; 53: 941-9.
– reference: Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009; 122: 78-86.
– reference: Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 931-9.
– reference: Vecchi C, Montosi G, Zhang K, et al. ER stress controls iron metabolism through induction of hepcidin. Science 2009; 325: 877-80.
– reference: Riva A, Trombini P, Mariani R, et al. Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J Gastroenterol 2008; 14: 4745-52.
– reference: Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011; 55: 920-32.
– reference: Dongiovanni P, Lanti C, Gatti S, et al. High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload. PLoS ONE 2015; 10: e0116855.
– reference: Valenti L, Fracanzani AL, Dongiovanni P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102: 1251-8.
– reference: Barisani D, Pelucchi S, Mariani R, et al. Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. J Hepatol 2008; 49: 123-33.
– reference: Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Diabetes Care 2013; 36: 309-15.
– volume: 117
  start-page: e218
  year: 2011
  end-page: 25
  article-title: Serum hepcidin: reference ranges and biochemical correlates in the general population
  publication-title: Blood
– volume: 11
  start-page: 1357
  year: 2011
  end-page: 66
  article-title: Molecular mechanisms regulating hepcidin revealed by hepcidin disorders
  publication-title: ScientificWorldJournal
– volume: 46
  start-page: 700
  year: 2007
  end-page: 7
  article-title: NAFLD and hyperinsulinemia are major determinants of serum ferritin levels
  publication-title: J Hepatol
– volume: 73
  start-page: 527
  year: 2010
  end-page: 36
  article-title: Hepcidin assay in serum by SELDI‐TOF‐MS and other approaches
  publication-title: J Proteomics
– volume: 325
  start-page: 877
  year: 2009
  end-page: 80
  article-title: ER stress controls iron metabolism through induction of hepcidin
  publication-title: Science
– volume: 32
  start-page: 131
  year: 2004
  end-page: 8
  article-title: The ferroportin disease
  publication-title: Blood Cells Mol Dis
– volume: 117
  start-page: 1155
  year: 1999
  end-page: 63
  article-title: Insulin resistance‐associated hepatic iron overload
  publication-title: Gastroenterology
– volume: 50
  start-page: 351
  year: 2009
  end-page: 7
  article-title: Liver iron excess in patients with hepatocellular carcinoma developed on non‐alcoholic steato‐hepatitis
  publication-title: J Hepatol
– volume: 23
  start-page: 57
  year: 2000
  end-page: 63
  article-title: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity
  publication-title: Diabetes Care
– volume: 14
  start-page: 4745
  year: 2008
  end-page: 52
  article-title: Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome
  publication-title: World J Gastroenterol
– volume: 27
  start-page: 2422
  year: 2004
  end-page: 8
  article-title: Serum ferritin and risk of the metabolic syndrome in U.S. adults
  publication-title: Diabetes Care
– volume: 20
  start-page: 3002
  year: 2014
  end-page: 10
  article-title: A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia
  publication-title: World J Gastroenterol
– volume: 122
  start-page: 78
  year: 2009
  end-page: 86
  article-title: The role of hepcidin in iron metabolism
  publication-title: Acta Haematol
– volume: 104
  start-page: 141
  year: 2011b
  end-page: 9
  article-title: Venesection for non‐alcoholic fatty liver disease unresponsive to lifestyle counselling – a propensity score‐adjusted observational study
  publication-title: QJM
– volume: 10
  start-page: e0116855
  year: 2015
  article-title: High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload
  publication-title: PLoS ONE
– volume: 29
  start-page: 2084
  year: 2006
  end-page: 9
  article-title: Relationships of serum ferritin, transferrin saturation, and HFE mutations and self‐reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study
  publication-title: Diabetes Care
– volume: 46
  start-page: 1291
  year: 2007
  end-page: 301
  article-title: Hemochromatosis: an endocrine liver disease
  publication-title: Hepatology
– volume: 182
  start-page: 2254
  year: 2013
  end-page: 63
  article-title: Dietary iron overload induces visceral adipose tissue insulin resistance
  publication-title: Am J Pathol
– volume: 50
  start-page: 1219
  year: 2009
  end-page: 25
  article-title: Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin
  publication-title: J Hepatol
– volume: 35
  start-page: 172
  year: 2003
  end-page: 8
  article-title: Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis
  publication-title: Dig Liver Dis
– volume: 28
  start-page: 2061
  year: 2005
  end-page: 3
  article-title: Prevalence of body iron excess in the metabolic syndrome
  publication-title: Diabetes Care
– volume: 94
  start-page: 1748
  year: 2009
  end-page: 52
  article-title: Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization
  publication-title: Haematologica
– volume: 21
  start-page: 568
  year: 2011a
  end-page: 75
  article-title: Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease
  publication-title: Nutr Metab Cardiovasc Dis
– volume: 31
  start-page: 994
  year: 2011
  end-page: 1000
  article-title: Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome
  publication-title: Liver Int
– volume: 55
  start-page: 920
  year: 2011
  end-page: 32
  article-title: Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target
  publication-title: J Hepatol
– volume: 102
  start-page: 1251
  year: 2007
  end-page: 8
  article-title: Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case‐control study
  publication-title: Am J Gastroenterol
– volume: 10
  start-page: e0134635
  year: 2015
  article-title: Iron stores, hepcidin, and aortic stiffness in individuals with hypertension
  publication-title: PLoS ONE
– volume: 94
  start-page: 1012
  year: 2012
  end-page: 9
  article-title: Hepatic iron stores are increased as assessed by magnetic resonance imaging in a Chinese population with altered glucose homeostasis
  publication-title: Am J Clin Nutr
– volume: 96
  start-page: 958
  year: 2011
  end-page: 61
  article-title: Insulin sensitivity and liver fat: role of iron load
  publication-title: J Clin Endocrinol Metab
– volume: 62
  start-page: 751
  year: 2015
  end-page: 61
  article-title: Increased duodenal iron absorption through up‐regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis
  publication-title: Hepatology
– volume: 53
  start-page: 448
  year: 2011
  end-page: 57
  article-title: Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease
  publication-title: Hepatology
– volume: 122
  start-page: 3529
  year: 2012
  end-page: 40
  article-title: Adipocyte iron regulates adiponectin and insulin sensitivity
  publication-title: J Clin Invest
– volume: 49
  start-page: 123
  year: 2008
  end-page: 33
  article-title: Hepcidin and iron‐related gene expression in subjects with Dysmetabolic Hepatic Iron Overload
  publication-title: J Hepatol
– volume: 53
  start-page: 927
  year: 2010b
  end-page: 33
  article-title: Beta‐globin mutations are associated with parenchymal siderosis and fibrosis in patients with non‐alcoholic fatty liver disease
  publication-title: J Hepatol
– volume: 138
  start-page: 905
  year: 2010a
  end-page: 12
  article-title: HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease
  publication-title: Gastroenterology
– volume: 122
  start-page: 931
  year: 2002
  end-page: 9
  article-title: Effect of iron depletion in carbohydrate‐intolerant patients with clinical evidence of nonalcoholic fatty liver disease
  publication-title: Gastroenterology
– volume: 154
  start-page: 333
  year: 2006
  end-page: 40
  article-title: Association between serum ferritin and the insulin resistance syndrome in a representative population
  publication-title: Eur J Endocrinol
– volume: 96
  start-page: 500
  year: 2011
  end-page: 6
  article-title: A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis
  publication-title: Haematologica
– volume: 146
  start-page: 1060
  year: 2014
  end-page: 9
  article-title: Gluconeogenic signals regulate iron homeostasis via hepcidin in mice
  publication-title: Gastroenterology
– volume: 51
  start-page: 1000
  year: 2002
  end-page: 4
  article-title: Blood letting in high‐ferritin type 2 diabetes: effects on insulin sensitivity and beta‐cell function
  publication-title: Diabetes
– volume: 36
  start-page: 309
  year: 2013
  end-page: 15
  article-title: Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study
  publication-title: Diabetes Care
– volume: 7
  start-page: e48804
  year: 2012
  article-title: The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease
  publication-title: PLoS ONE
– volume: 53
  start-page: 941
  year: 2010
  end-page: 9
  article-title: Ferroportin disease: a systematic meta‐analysis of clinical and molecular findings
  publication-title: J Hepatol
– volume: 24
  start-page: 471
  year: 2004
  end-page: 6
  article-title: Effects of venesections and restricted diet in patients with the insulin‐resistance hepatic iron overload syndrome
  publication-title: Liver Int
– ident: e_1_2_8_12_1
  doi: 10.1016/j.numecd.2010.01.003
– ident: e_1_2_8_4_1
  doi: 10.1530/eje.1.02083
– ident: e_1_2_8_44_1
  doi: 10.1016/j.jhep.2009.01.029
– ident: e_1_2_8_45_1
  doi: 10.3324/haematol.2009.010322
– ident: e_1_2_8_32_1
  doi: 10.1111/j.1478-3231.2011.02520.x
– ident: e_1_2_8_33_1
  doi: 10.1002/hep.21886
– ident: e_1_2_8_3_1
  doi: 10.1016/j.jhep.2011.05.008
– ident: e_1_2_8_5_1
  doi: 10.1016/j.jhep.2006.09.018
– ident: e_1_2_8_24_1
  doi: 10.2337/diabetes.51.4.1000
– ident: e_1_2_8_25_1
  doi: 10.1016/j.ajpath.2013.02.019
– ident: e_1_2_8_38_1
  doi: 10.1016/j.jprot.2009.08.003
– ident: e_1_2_8_21_1
  doi: 10.1093/qjmed/hcq170
– ident: e_1_2_8_28_1
  doi: 10.1371/journal.pone.0048804
– ident: e_1_2_8_39_1
  doi: 10.1126/science.1176639
– ident: e_1_2_8_6_1
  doi: 10.1016/S0016-5085(99)70401-4
– ident: e_1_2_8_26_1
  doi: 10.1172/JCI44421
– ident: e_1_2_8_22_1
  doi: 10.3748/wjg.v20.i11.3002
– ident: e_1_2_8_10_1
  doi: 10.1111/j.1572-0241.2007.01192.x
– ident: e_1_2_8_18_1
  doi: 10.1371/journal.pone.0134635
– ident: e_1_2_8_31_1
  doi: 10.1100/tsw.2011.130
– ident: e_1_2_8_2_1
  doi: 10.3748/wjg.14.4745
– ident: e_1_2_8_11_1
  doi: 10.1210/jc.2010-2682
– ident: e_1_2_8_23_1
  doi: 10.1111/j.1478-3231.2004.0988.x
– ident: e_1_2_8_36_1
  doi: 10.1182/blood-2011-02-337907
– ident: e_1_2_8_7_1
  doi: 10.1016/S1590-8658(03)00025-2
– ident: e_1_2_8_9_1
  doi: 10.2337/diacare.28.8.2061
– ident: e_1_2_8_41_1
  doi: 10.1016/j.bcmd.2003.08.003
– ident: e_1_2_8_40_1
  doi: 10.1053/j.gastro.2013.12.016
– ident: e_1_2_8_14_1
  doi: 10.2337/dc05-1592
– ident: e_1_2_8_15_1
  doi: 10.1053/j.gastro.2009.11.013
– ident: e_1_2_8_16_1
  doi: 10.1002/hep.24038
– ident: e_1_2_8_19_1
  doi: 10.2337/dc12-0505
– ident: e_1_2_8_35_1
  doi: 10.3324/haematol.2010.033449
– ident: e_1_2_8_27_1
  doi: 10.1159/000243791
– ident: e_1_2_8_17_1
  doi: 10.1016/j.jhep.2008.09.011
– ident: e_1_2_8_43_1
  doi: 10.1002/hep.27774
– ident: e_1_2_8_42_1
  doi: 10.1016/j.jhep.2010.05.016
– ident: e_1_2_8_20_1
  doi: 10.1053/gast.2002.32403
– ident: e_1_2_8_37_1
  doi: 10.2337/diacare.23.1.57
– ident: e_1_2_8_34_1
  doi: 10.1016/j.jhep.2008.03.011
– ident: e_1_2_8_29_1
  doi: 10.1016/j.jhep.2010.05.023
– ident: e_1_2_8_8_1
  doi: 10.2337/diacare.27.10.2422
– ident: e_1_2_8_13_1
  doi: 10.3945/ajcn.111.015743
– ident: e_1_2_8_30_1
  doi: 10.1371/journal.pone.0116855
SSID ssj0019951
Score 2.340654
Snippet Background & Aims Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose...
Dysmetabolic iron overload syndrome (DIOS) is a frequent condition predisposing to metabolic, cardiovascular and hepatic damage, whose pathogenesis remains...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1540
SubjectTerms Adult
Aged
Case-Control Studies
Female
Ferritins - blood
Hemochromatosis - complications
Hemoglobins - metabolism
Hepcidins - blood
Hepcidins - metabolism
hereditary haemochromatosis
Humans
iron
Iron - metabolism
Iron Overload - metabolism
Iron Overload - physiopathology
Italy
Linear Models
liver
Liver - pathology
Male
Middle Aged
Non-alcoholic Fatty Liver Disease - complications
nonalcoholic fatty liver disease
Young Adult
Title Hepcidin resistance in dysmetabolic iron overload
URI https://api.istex.fr/ark:/67375/WNG-SK69FVGS-R/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fliv.13124
https://www.ncbi.nlm.nih.gov/pubmed/26998752
https://www.proquest.com/docview/1819122302
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB5CAqWXNk362L5wSwm5eFnZsmzRUyjdbB_JIWnSHApCGsuwZOMN2d3S9Nd3Rn7QlBRKb36MjayZ0XwjjT4DvEmwcnLkMJbWVjFFiCIuhNexKCuNFK_zLJA9HxyqyYn8eJadrcHbbi9Mww_RT7ixZ4Txmh3cusVvTj6bfh-KlMITjb9cq8WA6KinjuKdxyHZkrz8TzGwZRXiKp7-yRuxaIO79cdtQPMmbg2BZ3wfvnVNbupNzoerpRvizz_YHP_zmzbhXgtIo73Ggh7Amq-3YHuvpmT84jraiUKJaJh734I7B-1K_DaIib_EKQW-iPJ1xqBkPBGdldeLC78ky5pNMeItdBHXiM7mtnwIJ-P3X95N4vb3CzGmKpWxHlVYOGZ4U06pUlibysIVKRLERfQpjxUExigjsUJZ4QpfUn6SVJpcXjks00ewXs9r_wQi1OgsWplh4WXulfZWqoSu6DTLhS4HsNspwmDLTc6_yJiZLkehnjGhZwbwuhe9bAg5bhPaCdrsJezVOVew5Zn5erhvjj8pPT7dPzZHA3jVqduQX_Fiia39fLUwgjNZsptRMoDHjR30b0sUJal5Rnd2gzb_3hDz-cNpOHj676LP4C6hMtVUDD6H9eXVyr8g5LN0L4OJ_wIXbPyD
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NTQJeGGx8lDEICE17SVUnjhNLvEyMrrC1D_uiL8iyHUeq1qXT1qJtfz13zocYGhLiLU4ukWPf-X5nn38G-BjZwvCesSHXugjRQ2RhxpwMWV5Ii_46TTzZ83AkBif82zgZL8GnZi9MxQ_RTriRZfjxmgycJqR_s_Lp5GeXxeifHsAKnehNzPm7hy15FO099uEWpwQA9II1rxDl8bSv3vFGK9Sw1_dBzbvI1bue_ir8aCpdZZycdRdz07W3f_A5_u9fPYUnNSYNdiolegZLrlyD9Z0S4_Hzm2Ar8Fmifvp9DR4O68X4dWADd2En6PsCDNkJhqL-BFjKb67O3RyVazqxAe2iCyhNdDrT-XM46X85_jwI6xMYQhuLmIeyV9jMEMmbMELkTOuYZyaLLaJca11MwwXiMQxKNBOamczlGKJEhUSrF8bm8QtYLmelewWBldZoq3liM8dTJ6TTXER4R8ZJymTege2mJ5St6cnplIypasIUbBnlW6YDH1rRi4qT4z6hLd-drYS-PKMktjRR30d76mhfyP7p3pE67MD7pr8Vmhatl-jSzRZXilEwi4rTizrwslKE9muRwDg1TfDJtu_Ov1dEHXw99Rev_130HTwaHA8PsDza34DHCNJElUD4Bpbnlwu3iUBobt56ff8F4EQArg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED8xkNBe9gH76Ma2DE2Il1R14jixeEJjpcCoEAzGwyTLvjhSRUkraKexv35n50NjYhLiLU4ukWPf-X5nn38G-BRhYXjPYMi1LkLyEFmYMStDlhcSyV-niSd7PhyKwSnfP0_OF2Cr2QtT8UO0E27OMvx47Qx8mhd_Gfl49LPLYnJPj2CJi5505zbsHLfcUW7rsY-2uFv_JydY0wq5NJ721VvOaMm166-7kOZt4Oo9T_8p_GjqXCWcXHTnM9PF3__QOT7wp57BkxqRBtuVCj2HBVuuwOp2SdH45U2wEfgcUT_5vgLLh_VS_CqwgZ3iiDxfQAG7A6GkPQGV8pvrSzsj1RqPMHB76AKXJDqe6PwFnPa_fPs8COvzF0KMRcxD2SswM47iTRghcqZ1zDOTxUgYF9HGbrAgNEYhiWZCM5PZnAKUqJBk88JgHr-ExXJS2tcQoESjUfMEM8tTK6TVXER0R8ZJymTegc2mIxTW5OTujIyxaoIUahnlW6YD663otGLkuEtow_dmK6GvLlwKW5qo78NddXIgZP9s90Qdd-Bj092KDMutlujSTubXirlQlvSmF3XgVaUH7dciQVFqmtCTTd-b_6-I-rp35i_e3F_0Aywf7fSpODx4C48JoYkqe3ANFmdXc_uOUNDMvPfa_gfebf9O
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hepcidin+resistance+in+dysmetabolic+iron+overload&rft.jtitle=Liver+international&rft.au=Rametta%2C+Raffaela&rft.au=Dongiovanni%2C+Paola&rft.au=Pelusi%2C+Serena&rft.au=Francione%2C+Paolo&rft.date=2016-10-01&rft.issn=1478-3231&rft.eissn=1478-3231&rft.volume=36&rft.issue=10&rft.spage=1540&rft_id=info:doi/10.1111%2Fliv.13124&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-3223&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-3223&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-3223&client=summon